Over the past five years, Waters Corporation has executed a comprehensive transformation plan that bolstered its commercial capabilities and revitalized its innovation pipeline. Under CEO Udit Batra’s leadership, the company streamlined operations, expanded its global salesforce by 12%, and improved its go-to-market efficiency. This strategic overhaul laid the groundwork for Waters to enter new high-growth segments and positioned it as a stronger competitor in regulated laboratory markets.

In late 2025, Waters closed its acquisition of Becton Dickinson’s Bioscience and Diagnostics unit for $1.8 billion, marking the company’s largest deal to date. This acquisition added a portfolio of immunoassay and flow cytometry products, estimated to generate $350 million in annual revenue, and expanded Waters’ addressable market by 20%. Management projects that synergies and cross-selling efforts will deliver $75 million in run-rate savings by fiscal 2027.

Waters continues to invest approximately 10% of product sales in research and development, focusing on next-generation mass spectrometry and chromatographic systems. The company’s installed base now exceeds 170,000 instruments across pharmaceutical, food safety and environmental testing laboratories worldwide. New product launches this year include a high-throughput LC-MS system capable of analyzing 1,200 samples per day, expected to drive recurring consumables sales.

Looking ahead, Waters forecasts mid-single-digit organic revenue growth and adjusted operating margins expanding by 100–150 basis points annually through 2028. The company aims to deliver annual free cash flow conversion above 70%, supported by disciplined capital spending and working capital improvements. Management highlighted plans for incremental bolt-on acquisitions in adjacent life sciences segments to sustain its long-term value creation trajectory.